The present efficacy of multiple sclerosis therapeutics
- 22 September 2009
- journal article
- Published by Ovid Technologies (Wolters Kluwer Health) in Neurology
- Vol. 73 (12), 984-990
- https://doi.org/10.1212/wnl.0b013e3181b9c8f7
Abstract
A challenge for the clinician treating patients with multiple sclerosis (MS) is to determine the most effective treatment while weighing the benefits and risks. Results of the phase 2 and phase 3 studies on natalizumab were received with great interest, in part due to the "improved" risk reduction for relapse rate, disease progression, and MRI metrics observed in comparison to results in trials of beta-interferon and glatiramer acetate. However, comparison across trials is invalid, in large part due to differences in the study populations. The increased efficacy observed in more recent trials has also been attributed to a fundamental change in subjects with MS enrolled in recent trials compared with the prior decade. In this article, we debate the relative efficacy of natalizumab vs the older injectable therapies.Keywords
This publication has 27 references indexed in Scilit:
- Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) studyThe Lancet Neurology, 2009
- Disease-modifying therapy in multiple sclerosisNeurology, 2008
- Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trialThe Lancet Neurology, 2008
- Quantitative risk-benefit analysis of natalizumabNeurology, 2008
- Temporal trends in the incidence of multiple sclerosisNeurology, 2008
- Health‐related quality of life in multiple sclerosis: effects of natalizumabAnnals of Neurology, 2007
- Incidence and prevalence of multiple sclerosis in Saskatoon, SaskatchewanNeurology, 2007
- Natalizumab reduces visual loss in patients with relapsing multiple sclerosisNeurology, 2007
- Copolymer 1 reduces relapse rate and improves disability in relapsing‐remitting multiple sclerosisNeurology, 1995
- New diagnostic criteria for multiple sclerosis: Guidelines for research protocolsAnnals of Neurology, 1983